PXD101 and Bortezomib in Treating Patients With Advanced Solid Tumors or Lymphomas

Inclusion Criteria: * Histologically or cytologically confirmed solid tumor or lymphoma that is refractory to standard therapy or for which no standard therapy exists * No active, untreated, or symptomatic brain metastases * Patients with treated brain metastases are eligible provided metastasis are stable and the patient is off all steroids and anticonvulsants * ECOG performance status 0-2 * Life expectancy ≥ 12 weeks * WBC ≥ 3,000/mm\^3 * Absolute neutrophil count ≥ 1,500/mm\^3 * Platelet count ≥ 100,000/mm\^3 * Bilirubin ≤ 1.5 mg/dL * AST and ALT ≤ 2.5 times upper limit of normal (ULN) (5 times ULN in the presence of liver metastases) * Creatinine ≤ 1.5 mg/dL OR creatinine clearance ≥ 60 mL/min * Not pregnant or nursing * Negative pregnancy test * Fertile patients must use effective contraception * No history of allergic reactions attributed to compounds of similar chemical or biologic composition to PXD101, bortezomib, boron, or mannitol * No peripheral neuropathy \> grade 1 * No uncontrolled intercurrent illness, including, but not limited to, any of the following: * Ongoing or active infection * Symptomatic congestive heart failure * Psychiatric illness or social situation that would preclude study requirements * No significant cardiovascular disease, including any of the following: * Myocardial infarction within the past 6 months * New York Heart Association class III-IV heart failure * Unstable angina pectoris * Uncontrolled hypertension * Condition requiring antiarrhythmic therapy * Ischemic or severe valvular heart disease * Acute ischemia or active conduction system abnormalities by ECG * No marked baseline prolongation of QT/QTc interval (repeated demonstration of a QTc interval \> 500 msec), long QT syndrome, or required use of concurrent medication during PXD101 administration that may cause torsade de pointes * No severe medical or psychiatric problems of that would preclude study compliance * At least 4 weeks since prior chemotherapy (6 weeks for nitrosoureas, carmustine, or mitomycin C) * At least 4 weeks since prior radiotherapy and recovered * At least 2 weeks since prior palliative radiotherapy to sites involving \< 35% of bone marrow reserve * At least 4 weeks since prior investigational agents * At least 2 weeks since prior valproic acid or any other histone deacetylase inhibitor * No prior stem cell or bone marrow transplantation * No concurrent radiotherapy or immunotherapy * No concurrent hormonal therapy * Luteinizing hormone-releasing hormone agonists, selective estrogen receptor modulators, or aromatase inhibitors as chronic maintenance therapy allowed * No concurrent combination antiretroviral therapy for HIV-positive patients * No other concurrent investigational agents * No other concurrent anticancer agents or therapies